-
Article
Open AccessMulti-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases
Melanoma brain metastases (MBM) are clinically challenging to treat and exhibit variable responses to immune checkpoint therapies. Prior research suggests that MBM exhibit poor tumor immune responses and are e...
-
Reference Work Entry In depth
Tregs
Regulatory T cells (Tregs) are a subtype of T cells with immune suppressive function and play a key role in immune self-tolerance. Its immune inhibitory function has been implicated as the important mechanism ...
-
Living Reference Work Entry In depth
Tregs
Regulatory T cells (Tregs) are a subtype of T cells with immune suppressive function and play a key role in immune self-tolerance. Its immune inhibitory function has been implicated as the important mechanism ...
-
Article
Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experience
To retrospectively evaluate the feasibility of arterial spin labeling (ASL) magnetic resonance imaging (MRI) for the assessment of vascularity of renal masses in patients with impaired renal function.
-
Article
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy
The availability of approved agents with distinct mechanisms of action (immunotherapy, vascular endothelial growth factor pathway, and mTOR inhibitors) has complicated treatment decisions for patients with adv...
-
Article
Multiphase contrast-enhanced helical CT of liver metastases from renal cell carcinoma
The aim of this study was to evaluate whether in patients with metastatic renal cell carcinoma (RCC) multiphase liver studies would improve detection of metastatic liver disease. Forty-six consecutive patients...
-
Article
Kidney cancer: The cytokine working group experience (1986–2001)
The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regar...
-
Article
Kidney cancer: The cytokine working group experience (1986–2001)
The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regar...
-
Article
Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon
The inflammatory tumor lymphocytic infiltrates and spontaneous tumor regressions seen in patients with metastatic malignant melanomas suggest a cellular immune involvement. Enhancement of such responses has be...
-
Article
Induction of circulating tumor necrosis factor (TNFα) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients
Fever is frequently observed in cancer patients treated with high-dose recombinant human interleukin-2 (rIL-2). The preincubation of rIL-2 with polymyxin B, an antibiotic that inhibits the biologic effects of ...
-
Article
The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)
Approximately 65% (11/17) of cancer patients participating in an ongoing Phase I clinical trial with recombinant interleukin-2 developed nonneutralizing serum IgG anti-interleukin-2 antibodies within 1 month o...